Evidence map›Paper›PMID 36639739›Full record

ArticleBMC genomics2023

Reporter gene assays and chromatin-level assays define substantially non-overlapping sets of enhancer sequences.

Daniel Lindhorst, Marc S Halfon

Abstract read
In one paragraph

Article in BMC genomics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Daniel LindhorstDepartment of Biochemistry, University at Buffalo-State University of New York, 955 Main St. #5128, Buffalo, NY, 14203, USA.
Marc S HalfonDepartment of Biochemistry, University at Buffalo-State University of New York, 955 Main St. #5128, Buffalo, NY, 14203, USA. mshalfon@buffalo.edu.

Funding

REDfly: The regulatory sequence resource for Drosophila and other insectsU24GM142435 · NIGMS · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI HALFON, MARC S · 2021 to 2023
$1.4M
National Science Foundation DBI-1758252NIGMS NIH HHS U24 GM142435NIH HHS U24 GM142435
6 · The paper itself

Abstract

backgroundTranscriptional enhancers are essential for gene regulation, but how these regulatory elements are best defined remains a significant unresolved question. Traditional definitions rely on activity-based criteria such as reporter gene assays, while more recently, biochemical assays based on chromatin-level phenomena such as chromatin accessibility, histone modifications, and localized RNA transcription have gained prominence.

resultsWe examine here whether these two types of definitions, activity-based and chromatin-based, effectively identify the same sets of sequences. We find that, concerningly, the overlap between the two groups is strikingly limited. Few of the data sets we compared displayed statistically significant overlap, and even for those, the degree of overlap was typically small (below 40% of sequences). Moreover, a substantial batch effect was observed in which experiment set rather than experimental method was a primary driver of whether or not chromatin-defined enhancers showed a strong overlap with reporter gene-defined enhancers.

conclusionsOur results raise important questions as to the appropriateness of both old and new enhancer definitions, and suggest that new approaches are required to reconcile the poor agreement among existing methods for defining enhancers.

Indexed as

ChromatinEnhancer Elements, GeneticChromosomesGene Expression RegulationGenes, ReporterChromatinATAC-seqCis-regulationCRMEnhancerGene regulationHistone modificationReporter gene

Identifiers

PMID36639739
PMCPMC9837977

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.